Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGRONOMICS LIMITED Net Asset Value 2013

Oct 18, 2013

7474_rns_2013-10-18_85013fd0-eb07-4afc-aa80-fa14333acefb.html

Net Asset Value

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8105Q

Port Erin Biopharma Investments Ltd

18 October 2013

Port Erin Biopharma Investments Limited

(the "Company")

Net Asset Value calculation to 30 September 2013

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2013 was 17.13 pence per share, including un-invested cash of £742,497 and an accrual of £353,041 for the management fee. The portfolio is valued under IFRS at bid price. This quarter's asset value before management fee represents an increase of 70.9% from the previous valuation of 10.63 pence per share, which included un-invested cash of £707,624. This excellent performance represents increase of 128% over the cash available for investment at inception after listing and operating costs."

Unaudited

to 30 September 2013

£
Fixed Assets
Investments 5,434,074
Current Assets
Debtors: amounts owing 9,219
Un-invested cash 742,497
Current Liabilities
Creditors: amounts due (32,049)
6,153,741
Capital and Reserves
Share Capital 34
Share Premium 2,759,551
Current year's earnings 2,553,790
Retained earnings 840,366
6,153,741
Shares in Issue 33,864,836
Asset Value per share pre management fee 18.17 pence
Management fee accrual 353,041
Net Asset Value per share 17.13 pence

--- ENDS ---

Portfolio Details

Investments as at 30 September 2013 Value % of Total Portfolio
Summit Corporation plc £1,341,666 24.7%
Plethora Solutions Holdings plc £968,749 17.8%
Arrowhead Research £562,557 10.4%
Synergy Pharmaceuticals Inc. £276,949 5.1%
Ampliphi Biosciences Corp. £207,319 3.8%
£3,357,243 61.8%
Aggregate value of remaining holdings below 3% of total portfolio £2,076,834 38.2%
TOTAL INVESTMENTS £5,434,074 100.0%

For further information, please contact:

Port Erin Biopharma Investments Ltd Libertas Capital Corporate Finance Limited Peterhouse Capital Limited
The Company Nomad Broker
Denham Eke

+44 162 463 9396
Sandy Jamieson

+44 203 697 9495
Jon Levinson

+44 207 469 0935

This information is provided by RNS

The company news service from the London Stock Exchange

END

NAVMMMMGNNFGFZM